Amibegron

Amibegron

SCHEMBL3824162

CCOC(=O)COc1ccc2c(c1)C[C@@H](NC[C@@H](O)c1cccc(Cl)c1)CC2

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB3

The experimentally established mechanism targets of Amibegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ADRB3 known ✓ P13945 12/20 0.91
ADRB1 P08588 2/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amibegron SCHEMBL8765764 1.00 ADRB3 (0.91) ADRB3ADRB1
Amibegron SCHEMBL2052478 1.00 ADRB3 (0.91) ADRB3ADRB1
Amibegron SCHEMBL3898164 1.00 ADRB3 (0.91) ADRB3ADRB1
Amibegron SCHEMBL29373533 1.00 ADRB3 (0.91) ADRB3ADRB1
Amibegron SCHEMBL6931932 1.00 ADRB3 (0.91) ADRB3ADRB1
Amibegron SCHEMBL5200899 1.00 ADRB3 (0.91) ADRB3ADRB1
Amibegron SCHEMBL9006793 1.00 ADRB3 (0.91) ADRB3ADRB1
Amibegron SCHEMBL3908665 1.00 ADRB3 (0.91) ADRB3ADRB1
Amibegron SCHEMBL9317343 0.99 ADRB3 (0.89) ADRB3ADRB1
Amibegron SCHEMBL3897916 0.99 ADRB3 (0.89) ADRB3ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0403360-B1 Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders SANOFI SA (FR) 1996-10-16 EP claimed
EP-0489640-B1 Use of phenylethanolaminotetralines for preparing antidepressant and anti-stress medicines SANOFI SA (FR) 1996-10-02 EP claimed
EP-0303546-B1 O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines SANOFI SA (FR) 1994-12-28 EP claimed
EP-0403360-A2 Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders SANOFI (FR) 1990-12-19 EP claimed
US-20140227289-A1 COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2014-08-14 US disclosed
WO-2012158123-A1 COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2012-11-22 WO disclosed
WO-2009109648-A1 PROCESS FOR PREPARING COMPOUNDS CONTAINING A HYDRONAPHTALENE STRUCTURE WITH AN UNSYMMETRICALLY SUBSTITUTED BENZENE RING SOLVIAS AG (CH) 2009-09-11 WO disclosed
EP-2098511-A1 Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring Solvias AG (CH) 2009-09-09 EP disclosed
EP-0403360-B1 Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders SANOFI SA (FR) 1996-10-16 EP disclosed
EP-0489640-B1 Use of phenylethanolaminotetralines for preparing antidepressant and anti-stress medicines SANOFI SA (FR) 1996-10-02 EP disclosed
EP-0303546-B1 O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines SANOFI SA (FR) 1994-12-28 EP disclosed
US-5236951-A Administering a phenylethanolamine derivative SANOFI (FR) 1993-08-17 US disclosed
EP-0403360-A2 Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders SANOFI (FR) 1990-12-19 EP disclosed
EP-0303546-A2 O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines SANOFI (FR) 1989-02-15 EP disclosed